| BNF Section/s |
Title |
Issuing Body |
Date of Issue |
Update Due |
| 6.9.2 |
Armour Thyroid - Position Statement Armour Thyroid
|
Kent & Medway CCG |
Jun 21 |
Jun 2023
|
| 6.8.1 |
Conception - Assisted Conception Service Specification
|
Kent and Medway NHS Standard contract |
2016/2017 |
- |
|
6.3.1.4
2.5.3
|
Dapagliflozin - Primary Care Guidance Dapagliflozin for Chronic Kidney Disease (CKD) in Adults |
Kent and Medway CCG |
Jun 2022 |
- |
|
6.3.1.4
2.5.3
|
Dapagliflozin - Dapagliflozin for treating chronic kidney disease TA775 |
NICE |
Mar 2022 |
- |
| 6.3.1.1 |
Degludec - Insulin degludec for type 1 diabetes in adults |
Kent & Medway PRGC |
Jan 2017 |
- |
| 6.3.1.1 |
Degludec -Insulin degludec (IDeg) for adults with type 2 diabetes mellitus |
Kent & Medway PRGC |
Mar 2019 |
- |
| 6.3.1.1 |
Degludec/Liraglutide - Insulin Degludec/Liraglutide (IdegLira; Xultophy) for type 2 diabetes mellitus |
Kent & Medway PRGC |
Nov 2015 |
- |
|
6.3.3
6.3.3.1 6.3.3.2
|
Diabetes Blood Glucose Monitoring- Guidelines for self-monitoring of blood glucose (SMBG) and ketone test strips and Lancets |
Kent & Medway ICB |
Aug 2023 |
Aug 2025 |
| 6.3.1 |
Diabetes - Guidelines for the Management of Type 2 Diabetes in Adults |
Kent & Medway ICB |
Aug 2022 |
Aug 2024 |
| 6.3.1.5 |
Diabetes -Type 1 diabetes in adults: diagnosis and management - NG17
|
NICE |
Mar 2022 |
|
| 6.3.1.5 |
Diabetes - (Type 1 and type 2) in children and young people: diagnosis and management - NG18 |
NICE |
Mar 2022 |
|
| 6.3.1.5 |
Diabetes - Type 2 diabetes in adults: management - NG 28
|
NICE |
Mar 2022 |
|
| 6.3.3.3 |
Flash Glucose Monitoring - Flash Glucose Monitoring System (FreeStyle Libre)Treatment Pathway |
Kent & Medway CCG |
Apr 2021 |
Apr 2023
|
| 6.3.3.3 |
|
Kent & Medway ICB |
Nov 2022 |
|
| 6.3.3.3 |
Glucose Monitoring - Interim support for prescribing Real Time Continuous Glucose Monitoring (rtCGM)
|
Kent & Medway ICB |
Mar 2023 |
|
| 6.8.1 6.8.1.2 6.8.1.3 6.8.1.4 7.6.3 |
HRT - Hormone Replacement Therapy (HRT) Prescribing Guidelines |
Kent & Medway ICB |
Apr 2023 |
Apr 2025 |
6.3.1.1
(Insulin Lispro) |
Insulin - High strength, fixed combination and biosimilar insulin products: minimising the risk of medication error |
MHRA
Drug Safety Update
|
Apr 2015 |
|
| 6.3.1.1 |
Insulin - Kent and Medway Guidance on Safe Insulin Prescribing - Version 1.0 |
Kent & Medway ICB
|
Oct 2023 |
Oct 2025 |
| 6.3.1.1 |
Insulin - Kent and Medway Guidance of Biosimilar Insulin Prescribing - Version 1.0 |
Kent & Medway ICB
|
Oct 2023 |
Oct 2025 |
| 6.3.3.4 |
Insulin Pen Needles - Guidance on insulin pen needles and preferred formulary choices for Kent and Medway |
Kent & Medway ICB |
Aug 2023 |
Aug 2025 |
| 6.9.2 |
Liothyronine - Position Statement Liothyronine prescribing |
Kent & Medway CCG |
Jun 2021 |
Jun 2023
|
| 6.9.2 |
Liothyronine - Liothyronine prescribing recommendations- Review of Existing Therapy for hypothyroidism |
Kent & Medway CCG |
Jun 2021 |
Jun 2023
|
| 6.4 |
Osteoporosis - Prevention of Osteoporosis in Post-menopausal Women - |
Medway CCG |
Jun 2014 |
Jun 2016
|
| 6.4.2.2 |
Raloxifene and Teriparatide - Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women - TA 161 |
NICE |
Feb 2018 |
- |
| 6.4.3 |
Romosozumab
|
High-Cost Drug
|
|
|
| 6.4.3 |
Romosozumab - Romosozumab for treating severe osteoporosis - TA791 |
NICE
|
May 2022 |
- |
| 6.3.1.4 |
SGLT2 - SGLT2 Inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin) risk of diabetic ketoacidosis |
MHRA
Drug Safety Update
|
Jun 2015 |
- |
| 6.3.1.4 |
SGLT2 - SGLT2i Top Tips NHS Kent & Medway Guidance |
Kent & Medway ICB
|
Oct 2023 |
Oct 2025 |
| 6.7.4 |
Somatrogon - Somatrogon for treating growth disturbance in children and young people aged 3 years and over - TA863
|
NICE
|
Feb 2023 |
|
| 6.4.2.2 |
Teriparatide - Teriparatide for osteoporosis |
Kent & Medway PRGC |
Jan 2016 |
|
|
6.8.1.5
6.8.2.1
|
Testosterone - Topical testosterone (Testogel): risk of harm to children following accidental exposure |
MHRA
Drug Safety Update
|
Jan 2023 |
|
|
6.3.1.4
|
Tirzepatide - Tirzepatide for treating type 2 diabetes TA924 |
NICE
|
Oct 2023 |
|
